Withdrawal of Dupilumab in Severe Asthma

Inclusion Criteria: * Adult patients ≥ 18 years old * Treated with dupilumab for at least 36 months for severe asthma * Well controlled asthma defined by an Asthma Control Questionnaire score ≥ 18 and 0 or 1 exacerbation within the year prior to the inclusion visit Exclusion Criteria: * Patients who refuse to discontinue dupilumab, for any reason * Patients with Forced expiratory volume in one second ≤ 30% of predicted values * Patients treated by an oral corticosteroid dose ≥ 10 mg/day (in prednisone equivalent) * Patients who have to discontinue dupilumab for a reason other than controlled asthma, such as an adverse drug reaction, a planned or current pregnancy, or a planned switch to another biologic indicated in severe asthma * Patients who have to continue dupilumab for the treatment of comorbidities apart from nasal polyposis * Active smoking * Pregnancy or breastfeeding